Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Dropped Head Syndrome: Report of Three Cases During Treatment with a Mek Inhibitor
Neurol 79:1929-1932, Chen, X.,et al, 2012
Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas are Associated with Improved Survival Compared with Matched Controls
AJNR 33:1763-1770, Mong, S.,et al, 2012
Rituximab Monotherapy for Patients With Recurrent Primary CNS Lymphoma
Neurol 76:929-930, Batchelor,T.T.,et al, 2011
Longitudinal Assessment of Oxaliplatin-Induced Neuropathy
Neurol 77:980-986, Burakgazi, A.Z.,et al, 2011
Intracranial Hemorrhage in Patients Treated with Bevacizumab and Low-Molecular Weight Heparin
Clin Adv Hematol Oncol 5:375-379, Nguyen, T.D.,et al, 2007
Clinicopath Conf, Diffuse Large B-Cell Lymphoma, EBV-Positive, with Immunosuppression
NEJM 354:1178-1184, Case 8-2006, 2006
Lhermitte's Sign Following Chemotherapy with Docetaxel
Neurol 50:563-564, van den Bent,M.J.,et al, 1998
Reversible Periph Neuropathy Induced by Single Admin of High-Dose Paclitaxel
Neurol 51:868-870, Iniquez,C.,et al, 1998
Peripheral Neuropathy Secondary to Docetaxel (Taxotere)
Neurol 46:108-111, 21996., New,P.Z.,et al, 1996
Peripheral Neurotoxicity Induced by Docetaxel
Neurol 46:104-108, 21996., Hilkens,P.H.E.,et al, 1996
Motor Neuropathy Due to Docetaxel and Paclitaxel
Neurol 47:115-118, Freilich,R.J.,et al, 1996
Vinorelbine Neurotoxicity:Clinical and Neurophysiological Findings in 23 Patients
JNNP 61:409-411, Pace,A.,et al, 1996
Assoc of Myasthenia Gravis with Extrathymic Hodgkin's Lymphoma:Resol of Myasth Sympt Following Antineopl Therapy
Neurol 45:1019, Abrey,L.E.&Askanas,V., 1995
Peripheral Neuropathy from Taxol and Cisplatin Combination Chemotherapy:Clinical and Electrophysiological Studies
Ann Neurol 35:304-311, Chaudhry,V.,et al, 1994
Taxol Neuropathy:Electrodiagnostic and Sural Nerve Biopsy Findings
Arch Neurol 51:726-729, Sahenk,Z.,et al, 1994
Intra-arterial Cisplatin-Associated Optic and Otic Toxicity
Arch Neurol 49:83-86, Maiese,K.,et al, 1992
Prevention of Cisplatin Neurotoxicity with an ACTH (4-9) Analogue in Patients with Ovarian Cancer
NEJM 322:89-94, 126-1271990., Gerritsen Van Der Hoop,R.,et al, 1990
Suramin-Induced Polyneuropathy
Neurol 40:954-960, LaRocca,R.V.,et al, 1990
Taxol Produces a Predominantly Sensory Neuropathy
Neurol 39:368-373, Lipton,R.B.,et al, 1989
Unusual Presentation of Cis-Platinum Neuropathy
Neurol 38:488-490, Mollman,J.E.,et al, 1988
Regional Nerve Injury After Intra-Arterial Chemotherapy
Neurol 37:834-837, Castellanos,A.M.,et al, 1987
Cisplatin Neuropathy with Lhermitte's Sign
JNNP 49:96-99, Dewar,J.,et al, 1986
Cisplatin Neuropathy
Cancer 54:1269-1275, Thompson,S.W.,et al, 1984
Diagnosis & Treatment of Lumbosacral Plexopathies in Patients with Cancer
Arch Neurol 41:1282-1285, Pettigrew,L.C.,et al, 1984
Neurotoxic Effects of Cisplatin Therapy
Arch Neurol 39:719-720, Walsh,T.J.,et al, 1982
Neurotoxicity of Commonly Used Antineoplastic Agents
NEJM 291:75, 1271974., Weiss,H.,et al, 1974
Neuropathy Due to Cytosine Arabinoside
BMJ 2:652-653, Russell,J.A.,et al, 1974
Vincristine Neurotoxicity
Ann Int Med 80:733-737, Rosenthal,S.,et al, 1974
The Neuromyopathy of Vincristine in Man, Clinical, Electrophysiol & Pathological Studies
J Neurol Sci 10:107-131, Bradley,W.G.,et al, 1970